XBIO Xenetic Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.5%
TTM net income YoY-16.0%
TTM EPS YoY24.0%
Revenue 3-yr CAGR7.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-129.6%
Net margin-123.7%
FCF margin—
EBITDA margin—
Returns
ROE-87.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.52x
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio3.15x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $725,257 | $660,601 | $806,923 | $766,296 | $1.03M | $589,897 | $593,261 | $648,820 |
| R&D expense | $520,663 | $552,013 | $661,443 | $773,416 | $756,482 | $656,557 | $879,029 | $1.04M |
| SG&A expense | $1.94M | $1.08M | $647,597 | $615,907 | $815,209 | $657,752 | $656,641 | $705,710 |
| Operating income | -$1.74M | -$971,690 | -$502,117 | -$623,027 | -$544,734 | -$724,412 | -$942,409 | -$1.10M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.70M | -$929,695 | -$456,382 | -$579,076 | -$509,940 | -$688,703 | -$903,141 | -$1.05M |
| EPS (basic) | -0.72 | -0.41 | -0.20 | — | -0.33 | -0.45 | -0.59 | — |
| EPS (diluted) | -0.72 | -0.41 | -0.20 | — | -0.33 | -0.45 | -0.59 | — |
| Weighted avg. shares (diluted) | 2.34M | 2.29M | 2.29M | — | 1.54M | 1.54M | 1.54M | — |
| Banking | ||||||||
| Net interest income | — | — | — | $43,792 | $30,783 | $34,232 | $39,190 | $51,867 |
| Balance sheet | ||||||||
| Cash & equivalents | $5.81M | $6.47M | $7.35M | $7.88M | $4.12M | $4.78M | $5.16M | $6.17M |
| Current assets | $6.00M | $6.65M | $7.60M | $8.05M | $5.07M | $5.35M | $5.48M | $6.59M |
| Total assets | $6.32M | $6.97M | $7.91M | $8.36M | $5.07M | $5.35M | $5.79M | $6.90M |
| Current liabilities | $1.90M | $894,977 | $958,239 | $968,025 | $1.11M | $903,430 | $667,927 | $894,263 |
| Total liabilities | $1.90M | $894,977 | $958,239 | $968,025 | $1.11M | $903,430 | $667,927 | $894,263 |
| Shareholders' equity | $4.41M | $6.07M | $6.95M | $7.40M | $3.96M | $4.45M | $5.12M | $6.01M |
| Shares outstanding | 2.34M | 2.34M | 2.29M | 2.29M | 1.54M | 1.54M | 1.54M | 1.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$662,131 | -$875,489 | -$536,377 | -$242,682 | -$658,247 | -$383,830 | -$1.00M | -$673,992 |
| Stock-based compensation | $36,022 | $51,964 | $11,312 | $13,998 | $15,855 | $15,683 | $19,251 | $25,108 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.